Modality
ASO
MOA
HPK1i
Target
KIF18A
Pathway
Wnt
Psoriasis
Development Pipeline
Preclinical
~Jan 2018
→ ~Apr 2019
Phase 1
Jul 2019
→ Oct 2031
Phase 1Current
NCT08677682
586 pts·Psoriasis
2025-08→2031-10·Not yet recruiting
NCT07107071
1,457 pts·Psoriasis
2019-07→2026-12·Recruiting
2,043 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-12-279mo awayPh2 Data· Psoriasis
2031-10-025.5y awayPh2 Data· Psoriasis
Trial Timeline
Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P1/2
Recruit…
P1/2
Not yet…
Catalysts
Ph2 Data
2026-12-27 · 9mo away
Psoriasis
Ph2 Data
2031-10-02 · 5.5y away
Psoriasis
RecruitingNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08677682 | Phase 1/2 | Psoriasis | Not yet recr... | 586 | eGFR |
| NCT07107071 | Phase 1/2 | Psoriasis | Recruiting | 1457 | DAS28 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1944 | Pfizer | NDA/BLA | APOC3 | |
| Niranesiran | Johnson & Johnson | Phase 2 | KIF18A | |
| NVS-6974 | Novartis | Preclinical | CD19 | |
| ABB-7516 | AbbVie | Phase 3 | PD-L1 | |
| Riluinavolisib | Moderna | NDA/BLA | KIF18A | |
| Bemanesiran | BioNTech | Phase 3 | PLK4 | |
| BII-5240 | Biogen | Phase 2/3 | MALT1 | |
| Semasacituzumab | Illumina | Phase 3 | Nectin-4 | |
| NUV-2032 | Nuvalent | Preclinical | KIF18A | |
| COR-9566 | Corcept | Approved | TYK2 |